Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Riera

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
ACS Medicinal Chemistry Letters|October 21, 2021
Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical StudiesJohn W Lampe, Joshua S Alford, P Ann Boriak-Sjodin, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Nature Communications|July 3, 2015
Crystallographic structure of a small molecule SIRT1 activator-enzyme complexHan Dai, April W Case, Thomas V Riera, et al.
Science (New York, N.Y.)|March 9, 2013
Evidence for a common mechanism of SIRT1 regulation by allosteric activatorsBasil P Hubbard, Ana P Gomes, Han Dai, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
ACS Medicinal Chemistry Letters|October 21, 2021
Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical StudiesJohn W Lampe, Joshua S Alford, P Ann Boriak-Sjodin, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Nature Communications|July 3, 2015
Crystallographic structure of a small molecule SIRT1 activator-enzyme complexHan Dai, April W Case, Thomas V Riera, et al.
Science (New York, N.Y.)|March 9, 2013
Evidence for a common mechanism of SIRT1 regulation by allosteric activatorsBasil P Hubbard, Ana P Gomes, Han Dai, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Pageof 4